Sailaja Puttagunta

Dr. Sailaja Puttagunta has served as Chief Medical Officer since December 2021, and previously served as the Vice President of Clinical Development from January 2016 to December 2018. From October 2019 to December 2021, Dr. Puttagunta served as chief medical officer at BiomX Inc., a public biotechnology company, and from December 2018 to October 2019, she served as chief medical officer of BiomX Ltd. until its merger with BiomX, Inc. in October 2019. From 2015 to 2016, Dr. Puttagunta served as vice president of medical affairs at Allergan plc, formerly Actavis plc. From August 2014 to December 2014, Dr. Puttagunta served as vice president of development and medical affairs at Durata Therapeutics, Inc., and from 2012 to 2014, she served as Durata’s executive director of clinical and medical affairs. From 2006 to 2012, Dr. Puttagunta served as a medical director at Pfizer Inc. Dr. Puttagunta graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an M.S. in Biochemistry from the New York University School of Medicine.